Literature DB >> 32808890

Risk of Nephrogenic Systemic Fibrosis in Stage 4 and 5 Chronic Kidney Disease Following Group II Gadolinium-based Contrast Agent Administration: Subanalysis by Chronic Kidney Disease Stage.

Prasad R Shankar1, Matthew S Davenport1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32808890     DOI： 10.1148/radiol.2020201492

Source DB:  PubMed          Journal:  Radiology        ISSN： 0033-8419            Impact factor:   11.105


× No keyword cloud information.
  3 in total

1.  Group II GBCM Can Be Used Safely for Imaging in Stage 4/5 CKD Patients: COMMENTARY.

Authors:  Ali K Abu-Alfa
Journal:  Kidney360       Date:  2020-12-03

Review 2.  Use of Intravenous Gadolinium-Based Contrast Media in Patients With Kidney Disease: Consensus Statements from the American College of Radiology and the National Kidney Foundation.

Authors:  Jeffrey C Weinreb; Roger A Rodby; Jerry Yee; Carolyn L Wang; Derek Fine; Robert J McDonald; Mark A Perazella; Jonathan R Dillman; Matthew S Davenport
Journal:  Kidney Med       Date:  2020-11-10

Review 3.  Improving Cancer Care for Patients With CKD: The Need for Changes in Clinical Trials.

Authors:  Ben Sprangers; Mark A Perazella; Stuart M Lichtman; Mitchell H Rosner; Kenar D Jhaveri
Journal:  Kidney Int Rep       Date:  2022-06-15
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.